Abstract:The tumor-suppressor protein p53 is tightly controlled in normal cells by its two negative regulators—the E3 ubiquitin ligase MDM2 and its homolog MDMX. Under stressed conditions such as DNA damage, p53 escapes MDM2- and MDMX-mediated functional inhibition and degradation, acting to prevent damaged cells from proliferating through induction of cell cycle arrest, DNA repair, senescence or apoptosis. Ample evidence suggests that stress signals induce phosphorylation of MDM2 and MDMX, leading to p53 activation. However, the structural basis of stress-induced p53 activation remains poorly understood because of the paucity of technical means to produce site-specifically phosphorylated MDM2 and MDMX proteins for biochemical and biophysical studies. Herein, we report total chemical synthesis, via native chemical ligation, and functional characterization of (24–108)MDMX and its Tyr99-phosphorylated analog with respect to their ability to interact with a panel of p53-derived peptide ligands and PMI, a p53-mimicking but more potent peptide antagonist of MDMX, using FP and surface plasmon resonance techniques. Phosphorylation of MDMX at Tyr99 weakens peptide binding by approximately two orders of magnitude. Comparative X-ray crystallographic analyses of MDMX and of pTyr99 MDMX in complex with PMI as well as modeling studies reveal that the phosphate group of pTyr99 imposes extensive steric clashes with the C-terminus of PMI or p53 peptide and induces a significant lateral shift of the peptide ligand, contributing to the dramatic decrease in the binding affinity of MDMX for p53. Because DNA damage activates c-Abl tyrosine kinase that phosphorylates MDMX at Tyr99, our findings afford a rare glimpse at the structural level of how stress-induced MDMX phosphorylation dislodges p53 from the inhibitory complex and activates it in response to DNA damage.

Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2

Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Inhibition of Nonsense-Mediated Decay Rescues Functional P53β/γ Isoforms in MDM2-amplified Cancers

Interrogation of MDM2 Phosphorylation in P53 Activation Using Native Chemical Ligation: the Functional Role of Ser17 Phosphorylation in MDM2 Reexamined

Structural modulation of p53TAD1-TAZ2 complex upon mutations and post-translational modification

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Real-time Surface Plasmon Resonance Monitoring of Site-Specific Phosphorylation of P53 Protein and Its Interaction with MDM2 Protein.

P53 Alpha-Helix Mimetics Antagonize P53/mdm2 Interaction and Activate P53.

Small Molecule Inhibitors of the P53-Mdm2

Structural adaptation of secondary p53 binding sites on MDM2 and MDMX

Characterization of cancer-associated missense mutations in MDM2

Activation of p53: how phosphorylated Ser15 triggers sequential phosphorylation of p53 at Thr18 by CK1δ

Structural Basis for High-Affinity Peptide Inhibition of P53 Interactions with MDM2 and MDMX.

Structural basis of how stress-induced MDMX phosphorylation activates p53

Characterizing the protein–protein interaction between MDM2 and 14-3-3σ; proof of concept for small molecule stabilization

MDM2: current research status and prospects of tumor treatment

Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53.

Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.